Loading company
BioAtla, Inc.
BCAB · Nasdaq · Healthcare · Biotechnology
$1.740.0%Sep 25 close
- 1M
- 0.0%
- 6M
- -77.5%
- 1Y
- -95.0%
- 5Y
- -99.9%
BCAB · Nasdaq · Healthcare · Biotechnology
$1.740.0%Sep 25 close
The quarter ending September 30, 2023, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2023 | 3 months toJun 30, 2022 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | $452K | -$18.7M | +102.42% |
| Profit per share | $0.27 | -$15.99 | +101.69% |
| Free Cash Flow | -$16.3M | -$30.8M | +47.16% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
BioAtla, Inc. has no earnings call transcript available.
“As we evaluate strategic paths forward, our focus remains on supporting the advancement of the ongoing Phase 1 study of BA3182 in adenocarcinomas, while preserving capital, and ensuring we maintain the flexibility to pursue all potential value-creating options,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
(CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager Antibody) BioAtla is developing BA3182 as a potential anticancer therapy for patients with advanced adenocarcinoma. BA3182 is a (CAB) EpCAM x (CAB) CD3 bispecific T cell engager antibody with binding sites for EpCAM and CD3ε designed to bind their respective targets specifically and reversibly under the conditions found in the tumor microenvironment (TME) and to have reduced binding outside of the TME. The CAB selective binding to both the CAB EpCAM and CAB CD3ε arms are required to activate the T cell engagement against the tumor, thus enabling the combined selectivity of each CAB binding arm in the bispecific antibody. BioAtla continues to advance the ongoing Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of BA3182 in advanced adenocarcinoma patients.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from BioAtla, Inc.’s Item 2.02 8-K filed March 31, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.